NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Edgewise Therapeutics, Inc. (EWTX) Stock Analysis

Edgewise Therapeutics, Inc. (EWTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

EWTX

$39.65

−$0.10 (−0.25%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EWTX with… →

EWTX Key Statistics

As of Oct 21, 2026
Trading
Open
$39.95
Previous Close
$39.75
Day's Range
39.46–40.78
52-Week Range
14.68–48.51
Volume
1.83M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.36
Valuation
Market Cap
$4.31B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.86
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$167.80M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
108.60M
1-Year Return
+155.64%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.41M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, EWTX closed at $39.65, +155.64% over 1 year.

Edgewise Therapeutics, Inc. (EWTX) has a market capitalization of $4.31B.

In fiscal 2025, EWTX reported revenue of $0.00.

EWTX Stock Return by Calendar Year

Edgewise Therapeutics, Inc. (EWTX) return since Mar 2021: what $10,000 became

1 year
$10,000 $25,564
+155.64%
5 years
$10,000 $23,324
+133.24%
Since Mar 2021
$10,000 $13,217
+32.17%

If you had invested $10,000 in Edgewise Therapeutics, Inc. (EWTX) at the close on March 26, 2021, the earliest close on record here, it would have been worth $13,217 at the close on October 21, 2026: +32.17% in total, +5.13% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+59.78%
2025−7.06%
2024+144.06%
2023+22.37%
2022−41.49%
2021 (partial year)−49.07%

As of October 21, 2026.

EWTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$167.80M—
2024$0.00−$133.81M—
2023$0.00−$100.16M—
2022$0.00−$67.64M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$191.41M−$167.80M—
2024$0.00—−$158.83M−$133.81M—
2023$0.00—−$114.36M−$100.16M—
2022$0.00—−$71.66M−$67.64M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Edgewise Therapeutics, Inc. (EWTX) is capitalised at $4.31B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 127.

EWTX last closed at $39.65 on October 21, 2026. That is −$0.10 (−0.25%) against the previous close. The 52-week range on file runs from $14.68 to $48.51. The latest close sits 170.19% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $167.80M. Earnings per share on a trailing basis come to −1.86.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 0.36. Daily returns over the trailing 5 years annualize to a volatility of 80.55%. Over the trailing twelve months the total return is +155.64%. Measured over 5 years, that is +18.46% a year compounded.

Growth & Income

No dividend is on file for EWTX.

So far in 2026 the total return is +59.78%. Across the complete calendar years on file, 2024 returned +144.06% and 2022 returned −41.49%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Edgewise Therapeutics, Inc. (EWTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Edgewise Therapeutics, Inc. EWTX $4.31B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Edgewise Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Visit website →